Literature DB >> 33562573

MicroRNA Profile for Diagnostic and Prognostic Biomarkers in Thyroid Cancer.

Jong-Lyul Park1,2, Seon-Kyu Kim2,3, Sora Jeon4, Chan-Kwon Jung4,5, Yong-Sung Kim1,6.   

Abstract

The challenge in managing thyroid nodules is to accurately diagnose the minority of those with malignancy. We aimed to identify diagnostic and prognostic miRNA markers for thyroid nodules. In a discovery cohort, we identified 20 candidate miRNAs to differentiate between noninvasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTP) and papillary thyroid carcinomas (PTC) by using the high-throughput small RNA sequencing method. We then selected three miRNAs (miR-136, miR-21, and miR-127) that were differentially expressed between the PTC follicular variant and other variants in The Cancer Genome Atlas data. High expression of three miRNAs differentiated thyroid cancer from nonmalignant tumors, with an area under curve (AUC) of 0.76-0.81 in an independent cohort. In patients with differentiated thyroid cancer, the high-level expression of the three miRNAs was an independent indicator for both distant metastases and recurrent or persistent disease. In patients with PTC, a high expression of miRNAs was associated with an aggressive histologic variant, extrathyroidal extension, distant metastasis, or recurrent or persistent disease. Three miRNAs may be used as diagnostic markers for differentiating thyroid cancers from benign tumors and tumors with extremely low malignant potential (NIFTP), as well as prognostic markers for predicting the risk of recurrent/persistent disease for differentiated thyroid cancer.

Entities:  

Keywords:  NIFTP; miR-127; miR-136; miR-21; miRNA; papillary thyroid carcinoma; thyroid neoplasms

Year:  2021        PMID: 33562573      PMCID: PMC7916038          DOI: 10.3390/cancers13040632

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  55 in total

1.  MiR-9 and miR-21 as prognostic biomarkers for recurrence in papillary thyroid cancer.

Authors:  Adriana Sondermann; Flavia Maziero Andreghetto; Ana Carolina Bernardini Moulatlet; Elivane da Silva Victor; Marilia Germanos de Castro; Fábio Daumas Nunes; Lenine Garcia Brandão; Patricia Severino
Journal:  Clin Exp Metastasis       Date:  2015-05-26       Impact factor: 5.150

2.  Korea's thyroid-cancer "epidemic"--screening and overdiagnosis.

Authors:  Hyeong Sik Ahn; Hyun Jung Kim; H Gilbert Welch
Journal:  N Engl J Med       Date:  2014-11-06       Impact factor: 91.245

3.  MicroRNA-127 is a tumor suppressor in human esophageal squamous cell carcinoma through the regulation of oncogene FMNL3.

Authors:  Xuhui Gao; Xuelian Wang; Kaican Cai; Wujun Wang; Qun Ju; Xiyao Yang; Haofei Wang; Hua Wu
Journal:  Eur J Pharmacol       Date:  2016-09-17       Impact factor: 4.432

4.  MiR-136 promotes apoptosis of glioma cells by targeting AEG-1 and Bcl-2.

Authors:  Yi Yang; Jueheng Wu; Hongyu Guan; Junchao Cai; Lishan Fang; Jun Li; Mengfeng Li
Journal:  FEBS Lett       Date:  2012-08-09       Impact factor: 4.124

5.  Comprehensive DNA Methylation Profiling Identifies Novel Diagnostic Biomarkers for Thyroid Cancer.

Authors:  Jong-Lyul Park; Sora Jeon; Eun-Hye Seo; Dong Hyuck Bae; Young Mun Jeong; Yourha Kim; Ja Seong Bae; Seon-Kyu Kim; Chan Kwon Jung; Yong Sung Kim
Journal:  Thyroid       Date:  2020-01-09       Impact factor: 6.568

6.  MicroRNA-791 is an independent prognostic factor of papillary thyroid carcinoma and inhibits the proliferation of PTC cells.

Authors:  X-B Gao; C-L Chen; Z-L Tian; F-K Yuan; G-L Jia
Journal:  Eur Rev Med Pharmacol Sci       Date:  2018-09       Impact factor: 3.507

7.  Stability of Circulating Blood-Based MicroRNAs - Pre-Analytic Methodological Considerations.

Authors:  Charlotte Glinge; Sebastian Clauss; Kim Boddum; Reza Jabbari; Javad Jabbari; Bjarke Risgaard; Philipp Tomsits; Bianca Hildebrand; Stefan Kääb; Reza Wakili; Thomas Jespersen; Jacob Tfelt-Hansen
Journal:  PLoS One       Date:  2017-02-02       Impact factor: 3.240

8.  Highly prevalent BRAF V600E and low-frequency TERT promoter mutations underlie papillary thyroid carcinoma in Koreans.

Authors:  Sue Youn Kim; Taeeun Kim; Kwangsoon Kim; Ja Seong Bae; Jeong Soo Kim; Chan Kwon Jung
Journal:  J Pathol Transl Med       Date:  2020-06-15

9.  Expression profile and clinical significance of microRNAs in papillary thyroid carcinoma.

Authors:  You Peng; Chen Li; Ding-Cun Luo; Jin-Wang Ding; Wo Zhang; Gang Pan
Journal:  Molecules       Date:  2014-08-05       Impact factor: 4.411

View more
  5 in total

1.  Expression Profile and Diagnostic Significance of MicroRNAs in Papillary Thyroid Cancer.

Authors:  Mariusz Rogucki; Iwona Sidorkiewicz; Magdalena Niemira; Janusz Bogdan Dzięcioł; Angelika Buczyńska; Agnieszka Adamska; Katarzyna Siewko; Maria Kościuszko; Katarzyna Maliszewska; Anna Wójcicka; Jakub Supronik; Małgorzata Szelachowska; Joanna Reszeć; Adam Jacek Krętowski; Anna Popławska-Kita
Journal:  Cancers (Basel)       Date:  2022-05-28       Impact factor: 6.575

Review 2.  Emerging Biomarkers in Thyroid Practice and Research.

Authors:  Shipra Agarwal; Andrey Bychkov; Chan-Kwon Jung
Journal:  Cancers (Basel)       Date:  2021-12-31       Impact factor: 6.639

Review 3.  Noninvasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features (NIFTP): Tumour Entity with a Short History. A Review on Challenges in Our Microscopes, Molecular and Ultrasonographic Profile.

Authors:  Ivana Kholová; Elina Haaga; Jaroslav Ludvik; David Kalfert; Marie Ludvikova
Journal:  Diagnostics (Basel)       Date:  2022-01-20

4.  Transcriptomic Analysis of Papillary Thyroid Cancer: A Focus on Immune-Subtyping, Oncogenic Fusion, and Recurrence.

Authors:  Seung-Jin Park; Yea Eun Kang; Jeong-Hwan Kim; Jong-Lyul Park; Seon-Kyu Kim; Seung-Woo Baek; In Sun Chu; Shinae Yi; Seong Eun Lee; Young Joo Park; Eun-Jae Chung; Jin Man Kim; Hye Mi Ko; Je-Ryong Kim; Seung-Nam Jung; Ho-Ryun Won; Jae Won Chang; Bon Seok Koo; Seon-Young Kim
Journal:  Clin Exp Otorhinolaryngol       Date:  2022-03-04       Impact factor: 3.340

5.  Onco-miR-21 Promotes Stat3-Dependent Gastric Cancer Progression.

Authors:  Janson Tse; Thomas Pierce; Annalisa L E Carli; Mariah G Alorro; Stefan Thiem; Eric G Marcusson; Matthias Ernst; Michael Buchert
Journal:  Cancers (Basel)       Date:  2022-01-06       Impact factor: 6.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.